Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1-43/IL-10 cDNA

Vaccine

Volumn 29, Issue 43, 2011, Pages 7474-7482

  Hara, Hideo ^a   Mouri, Akihiro ^b,c   Yonemitsu, Yoshikazu ^d   Nabeshima, Toshitaka ^b,c   Tabira, Takeshi ^e,f  

^a SAGA UNIVERSITY   (Japan)

^b MEIJO UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^f JUNTENDO UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Amyloid; Immunotherapy; Sendaivirus vector

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-43]; COMPLEMENTARY DNA; OLIGOMER; RECOMBINANT INTERLEUKIN 10; SENDAI VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; ASSOCIATION CORTEX; BRAIN HOMOGENATE; COGNITION; CONDITIONING; CONTROLLED STUDY; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEAR; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOTHERAPY; LEARNING DISORDER; MAZE TEST; MEMORY DISORDER; MICROGLIA; MOUSE; MUCOSAL IMMUNOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONTENT; SYNAPSE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; COGNITION; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; GENE THERAPY; GENETIC VECTORS; IMMUNITY, MUCOSAL; IMMUNOTHERAPY; INTERLEUKIN-10; MAZE LEARNING; MICE; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; SENDAI VIRUS; VACCINATION;

EID: 80053439054     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.057     Document Type: Article

References (40)

1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
2. Weiner H.L., Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006, 6:404-416.
3. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
4. Orgogozo J.-M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
5. Nicoll J.A.R., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9:448-452.
6. Ferrer I., Rovira M.B., Guerra M.L.S., Rey M.J., Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004, 14:11-21.
7. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129-131.
8. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
9. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
10. Vellas B., Black R., Thal L.J., Fox N.C., Daniels M., McLennan G., et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009, 6:144-151.
11. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
12. Bard F., Cannon C., Barbour R., Burke R.-L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
13. Dodart J.-S., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002, 5:452-457.
14. Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 732061-732070.
15. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2001, 298:1379.
16. Racke M.M., Boone L.I., Hepburn D.L., Parsadainian M., Bryan M.T., Ness D.K., et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005, 25:629-636.
17. 1-42 trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 2009, 302:1796-1802.
18. Okura Y., Miyakoshi A., Kohyama K., Park I.-K., Stanfenbial M., Matsumoto Y. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects safety. Proc Natl Acad Sci USA 2006, 103:9619-9624.
19. Weiner H.L., Lemere C.A., Maron R., Maron R., Spooner E.T., Grenfell T.J., et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000, 48:567-579.
20. Maier M., Seabrook T.J., Lazo N.D., Jiang L., Das P., Janus C., et al. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 2006, 26:4717-4728.
21. Hara H., Monsomego A., Yuasa K., Adachi K., Takeda S., Takahashi K., et al. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimer Dis 2004, 6:483-488.
22. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
23. Li H.-O., Zhu Y.-F., Asakawa M., Kuma H., Hirata T., Ueda Y., et al. Cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 2000, 74:6564-6569.
24. Inoue M., Tokusumi Y., Ban H., Kanaya T., Tokusumi T., Nagai Y., et al. Nontransmissible virus-like particle formation by F-deficient Sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. J Virol 2003, 77:3238-3246.
25. Bitzer M., Ungerechts G., Bossow S., Graepler F., Sedlmeier R., Armeanu S., et al. Negative-strand RNA, viral vectors: intravenous application of Sendai virus vectors for the systemic delivery of therapeutic genes. Mol Ther 2003, 7:210-217.
26. Hirata T., Iida A., Shiraki-Iida T., Kitazato K., Kato A., Nagai Y., et al. An improved method for recovery of F-defective Sendai virus expressing foreign genes from cloned cDNA. J Virol Methods 2002, 104:125-133.
27. Inoue M., Tokusumi Y., Ban H., Shirakura M., Kanaya T., Yoshizaki M., et al. Recombinant Sendai virus vectors deleted in both the matrix and the fusion genes: efficient gene transfer with preferable properties. J Gene Med 2004, 6:1069-1081.
28. Matsubara E., Bryant-Thomas T., Pacheco Quinto J., Henry T.L., Poeggeler B., Herbert D., et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003, 85:1101-1108.
29. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
30. Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T., Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 2007, 21:2135-2148.
31. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med 2010, 220:95-106.
32. Frenkel D., Maron R., Burt D.S., Weiner H.L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 2005, 115:2423-2433.
33. Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophi E., Landa G., Cohen H., et al. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci USA 2006, 103:11784-11789.
34. Hurwitz J.L., Soike K.F., Sangster M.Y., Portner A., Sealy R.E., Dawson D.H., et al. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine 1997, 15:533-540.
35. Slobod K.S., Shenep J.L., Luján-Zilbermann J., Allison K., Brown B., Scroggs R.A., et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004, 22:3182-3186.
36. Zhan X., Slobod K.S., Krishnamurthy S., Luque L.E., Takimoto T., Jones B., et al. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. Vaccine 2008, 26:3480-3488.
37. Jones B., Zhan X., Mishin V., Slobod K.S., Surman S., Russell C.J., et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine 2009, 27:1848-1857.
38. Lazarov O., Lee M., Peterson D.A., Sisodia S.S. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 2002, 22:9785-9793.
39. Ribaut-Barassin C., Dupont J.L., Haeberle A.M., Bombarde G., Huber G., Moussaoui S., et al. Alzheimer's disease proteins in cerebellar and hippocampal synapses during postnatal development and aging of the rat. Neuroscience 2003, 120:405-423.
40. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.